Trial Profile
LAPATINIB plus LETROZOLE or CAPECITABINE AS FIRST LINE TREATMENT OF ER+/HER2+ METASTIC BREAST CANCER - A phase IIb randomized study with built-in crossover
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2013
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Tipicall
- 29 Dec 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 20 Jun 2011 New trial record